Abstract:The cardiovascular complications contribute to a majority of diabetes associated morbidity and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus (DM) and 52% of deaths in type 2 DM. Diabetes elicits cardiovascular dysfunction through 2 major mechanisms: ischemic and non-ischemic. Non-ischemic injury is usually under-recognized although common in DM patients, and also a pathogenic factor of heart failure in those diabetic individuals complicated with ischemic heart disease. Diabetic cardiomyopathy (DCM) is defined as a heart disease in which the myocardium is structurally and functionally abnormal in the absence of coronary artery disease, hypertensive, valvular, or congenital heart disorders in diabetic patients, theoretically caused by non-ischemic injury solely. Current therapeutic strategies targeting DCM mainly address the increased blood glucose levels, however, the effects on heart function are disappointed. Accumulating data indicate endothelial dysfunction plays a critical role in the initiation and development of DCM. Hyperglycemia, hyperinsulinemia, and insulin resistance cause the damages of endothelial function, including barrier dysfunction, impaired nitric oxide (NO) activity, excessive reactive oxygen species (ROS) production, oxidative stress, and inflammatory dysregulation. In turn, endothelial dysfunction promotes impaired myocardial metabolism, intracellular Ca 2+ mishandling, endoplasmic reticulum (ER) stress, mitochondrial defect, accumulation of advanced glycation end products, and extracellular matrix (ECM) deposit, leads to cardiac stiffness, fibrosis, and remodeling, eventually results in cardiac diastolic dysfunction, systolic dysfunction, and heart failure. While endothelial dysfunction is closely related to cardiac dysfunction and heart failure seen in DCM, clinical strategies for restoring endothelial function are still missing. This review summarizes the timely findings related to the effects of endothelial dysfunction on the disorder of myocardium as well as cardiac function, provides mechanical insights in pathogenesis and pathophysiology of DCM developing, and highlights potential therapeutic targets.

Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

Epigenetics in diabetic cardiomyopathy

[Histone methylation and diabetic cardiomyopathy]

Histone deacetylases and inhibitors in diabetes mellitus and its complications

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

Molecular mechanisms of metabolic dysregulation in diabetic cardiomyopathy

Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions

Targeting Autophagy in Diabetic Cardiomyopathy: from Molecular Mechanisms to Pharmacotherapy

Role of the Cathepsin K/Calcineurin/Nuclear Factor of Activated T-cells Axis in the Pathogenesis and Management of Diabetic Cardiomyopathy

Analysis of differentially expressed genes related to the development of diabetic cardiomyopathy in the myocardium of type-2 diabetic rats

Targeting histone deacetylase in cardiac diseases

Application of Animal Models in Diabetic Cardiomyopathy

Epigenetics of methylation modifications in diabetic cardiomyopathy

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Post‐translational modifications in diabetic cardiomyopathy

Mitochondria-Endoplasmic Reticulum Contacts: The Promising Regulators in Diabetic Cardiomyopathy

Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues

Endothelial Dysfunction and Diabetic Cardiomyopathy

Novel histone post-translational modifications in diabetes and complications of diabetes: The underlying mechanisms and implications

Mitochondria-associated endoplasmic reticulum membrane (MAM): a dark horse for diabetic cardiomyopathy treatment